RJA
PRTK

Raymond James & Associates’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Raymond James & Associates’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-11,000
Closed -$2K – 4297
2021
Q2 		$2K Buy
+11,000
New +$88.9K ﹤0.01% 4074
2020
Q4 		– Sell
-22,000
Closed -$51K – 3901
2020
Q3 		$51K Buy
+22,000
New +$109K ﹤0.01% 3442

Other funds holding PRTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
BC
Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return
GAI
General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Raymond James & Associates's PRTK Position: Q3 2021 in Review

Raymond James & Associates sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2021, closing a stake of 29,198 shares — an estimated $199K sold.

Raymond James & Associates first reported a position in PRTK in Q3 2017 and held it in 16 quarters. The position peaked at $1.15M in Q1 2018. 105 funds tracked by Wall St. Rank hold PRTK as of Q3 2021.

  • Raymond James & Associates reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
  • Raymond James & Associates sold 29,198 Paratek Pharmaceuticals, Inc. shares in Q3 2021, an estimated $199K.
  • Raymond James & Associates first reported a position in Paratek Pharmaceuticals, Inc. in Q3 2017 and held it in 16 quarters.
  • Raymond James & Associates's Paratek Pharmaceuticals, Inc. position peaked at $1.15M in Q1 2018.
  • 105 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2021.

Based on Raymond James & Associates's 13F filing for Q3 2021, filed 2 Nov 2021.